Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) EBIT (2019 - 2025)

Avidity Biosciences' EBIT history spans 7 years, with the latest figure at -$254.5 million for Q4 2025.

  • For Q4 2025, EBIT fell 110.33% year-over-year to -$254.5 million; the TTM value through Dec 2025 reached -$745.9 million, down 96.85%, while the annual FY2025 figure was -$745.9 million, 96.85% down from the prior year.
  • EBIT reached -$254.5 million in Q4 2025 per RNA's latest filing, down from -$188.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$23.9 million in Q1 2021 to a low of -$254.5 million in Q4 2025.
  • Average EBIT over 5 years is -$82.9 million, with a median of -$58.1 million recorded in 2023.
  • Peak YoY movement for EBIT: crashed 287.92% in 2021, then fell 13.68% in 2023.
  • A 5-year view of EBIT shows it stood at -$38.5 million in 2021, then crashed by 38.08% to -$53.2 million in 2022, then dropped by 25.4% to -$66.7 million in 2023, then crashed by 81.28% to -$121.0 million in 2024, then plummeted by 110.33% to -$254.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's EBIT are -$254.5 million (Q4 2025), -$188.8 million (Q3 2025), and -$171.1 million (Q2 2025).